TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06620679

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide (LPS)
Description: Lipopolysaccharide (LPS), single i.v. bolus, 0.4 ng/kg body weight

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide (LPS)
Description: Lipopolysaccharide (LPS), single i.v. bolus, 0.4 ng/kg body weight

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline, single i.v. bolus, in equal volume to intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline, single i.v. bolus, in equal volume to intervention
Study: NCT04866004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management - Cannabis
Description: Participants in the contingency management program will be provided financial incentives for 28-days of cannabis abstinence. At every visit, participants will provide urine samples for the biochemical verification of cannabis abstinence). Participants with evidence of cannabis abstinence will be provided a financial incentive that increases across subsequent study visits.
Study: NCT06621394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutritional intervention
Description: nutritional intervention to mediterranean diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutritional intervention
Description: nutritional intervention to mediterranean diet
Study: NCT06653556

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LCAR-AIO T cells
Description: Before treatment with LCAR-AIO T cells, subjects will receive a conditioning regimen.
Study: NCT06665594

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA)
Description: Injectable gel
Study: NCT05752955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMARThealth Pregnancy
Description: At each visit, the CHW will:~* Update history and contact details~* Check haemoglobin with a point of care device.~* Check BP~* Check iron folic acid (IFA) supply and compliance~* Brief screen for mental health problems~An electronic decision support platform will provide advice if referral is needed. At the Primary Health Centre, doctor/s will be issued a tablet computer with a version of the SMARThealth Pregnancy App to:~* Generate an automated list of all patients in the community who require review, with the dates of testing and referral, and with two-way communication back to the CHW.~* Suggest management based on current Indian guidelines for the diagnosis and management of anaemia, hypertension and diabetes in pregnant and non-pregnant adults.
Study: NCT06621394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Eating
Description: intervention regarding mindful eating, e.g. attention while eating, apprechiation of food

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Eating
Description: intervention regarding mindful eating, e.g. attention while eating, apprechiation of food

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Attention Control
Description: Befreinding Control Group: Provision of same amout of time and attention, without having an intervention, e.g. talking about hobbies and interests, playing card games
Study: NCT06621979

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bypass surgery type one anastomosis gastric bypass
Description: Adult patients who have undergone single-anastomosis gastric bypass followed by fundoplication of the excluded stomach for the treatment of disabling post-bypass gastroesophageal reflux, resistant to medical treatment and requiring surgical intervention.
Study: NCT06618391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: Envolimab :150 mg/time, intratumoral injection, at least 5 sites; Recombinant human endostatin： Q3W for 4-6 cycles，Maintenance therapy 210 mg ,CIV 72 hours ,administered as continuous intravenous pump, administered on Day 1 of each cycle; Docetaxel: 60-75 mg/m2, D1, Q3W,for 4-6 cycles，intravenous drip.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human endostatin
Description: Recombinant human endostatin: 15mg/time, intratumoral injection, at least 5 sites; Envolimab :Maintenance therapy 300 mg, Q3W for 4-6 cycles，, subcutaneous injection; administered on Day 1 of each cycle; Docetaxel: 60-75 mg/m2, D1, Q3W,for 4-6 cycles，intravenous drip.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human adenovirus type 5
Description: Recombinant Human Adenovirus Type 5: 1.0ml/time, intratumoral injection, at least 5 sites; Envolimab :Maintenance therapy 300 mg, Q3W for 4-6 cycles，, subcutaneous injection; administered on Day 1 of each cycle; Docetaxel: 60-75 mg/m2, D1, Q3W,for 4-6 cycles，intravenous drip.
Study: NCT06620536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: Electrical stimulation of peripheral nerves for the recovery of hand function in tetraplegic patients of fundamental importance in improving quality of life.
Study: NCT06683963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rebee
Description: Tablet device with accompanying sensor device. Tablet device is preloaded with exercises, to be taught to patients during their hospital stay, and to be continued post-discharge
Study: NCT06685601

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tPBM（active）
Description: During the active stimulation condition, participants will receive a single session of tPBM intervention, lasting 12 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tPBM（sham）
Description: During the sham stimulation condition, participants will receive the same intervention with identical target areas and wavelength, but only for the first and last 30 seconds of the session.
Study: NCT06684951

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: observe hCG effect on endometrial receptivity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: observe hCG effect on endometrial receptivity
Study: NCT06621160

Intervention type: OTHER
Intervention: Observation
Description: After the participants\&#39; physical and sociodemographic characteristics were recorded, they were asked to fill out the Constipation Severity Scale and 7- Day Stool Diary to determine their constipation levels. The individuals\&#39; anthropometric characteristics were assessed with triceps, subscapula, suprailiac and calf skinfold thickness, humerus and femur epicondyle diameter, biceps and calf circumference measurements, spinal postures were assessed with the Spinal Mouse, and physical activity levels were assessed with the International Physical Activity Questionnaire-Short Form UFAA-KF and pedometer.

Intervention type: OTHER
Intervention: Observation
Description: After the participants\&#39; physical and sociodemographic characteristics were recorded, they were asked to fill out the Constipation Severity Scale and 7- Day Stool Diary to determine their constipation levels. The individuals\&#39; anthropometric characteristics were assessed with triceps, subscapula, suprailiac and calf skinfold thickness, humerus and femur epicondyle diameter, biceps and calf circumference measurements, spinal postures were assessed with the Spinal Mouse, and physical activity levels were assessed with the International Physical Activity Questionnaire-Short Form UFAA-KF and pedometer.
Study: NCT06621849

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae plane block
Description: In the erector spinae plane block (group E), an ultrasound-guided block will be performed on the ipsilateral side of the surgery while the patient is in lateral position 3-5 cm from the midline (10). Moving cephalic from the sacrum, we will identify the L5, L4, and L3 transverse processes and erector spinae muscles posteriorly. A 21 G and 70mm length needle will be directed in-plane, and the needle tip will be positioned anterior to the erector spinae muscle at the corner of the transverse process. After the initial saline injection, dissection of the plane will be observed by injecting a total volume of 20 ml composed of 10 micrograms dexmedetomidine in 2ml of normal saline and 18 ml of bupivacaine 0.25%, which is far from the toxic dose (10). Correct placement is defined as the spread of local anesthetic cranially and caudally from the injection point, dissecting the plane between the transverse processes and erector spinae muscles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: patients will receive 5 ml of subcutaneous lidocaine 1% then 3.5 ml of bupivacaine 0.5% and 0.1 mg of morphine in 0.25 ml of normal saline intrathecal
Study: NCT06502795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protected Range Quadriceps Strengthening group
Description: Warm-up: Start with 5 minutes of stationary biking. Then, proceed with two sets of 30-second dynamic stretches targeting the quadriceps, hamstrings, calf muscles, and adductors, followed by static stretching for the abductors.~Strengthening: Complete 3 sets of 8-12 repetitions for each exercise, aiming for a perceived effort level on the Borg scale between 60% and 80%. Increase the load by 2%-10% when the patient can perform 14 or more repetitions in the final set while maintaining the Borg scale between 60% and 80%.~For the Leg Extension Machine, maintain a range of motion between 90 to 45 degrees. During Squats and Bulgarian Squats, aim for a range of motion between 0 to 45 degrees.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient-Guided Range Quadriceps Strengthening group
Description: Warm-up: 5 minutes of stationary biking. Next, perform two sets of 30-second stretches for the quadriceps, hamstrings, calf muscles, adductors and abductors hip.~Strengthening: Patients will complete 3 sets of 8 to 12 repetitions for each exercise, aiming for a perceived effort level of 60% to 80% on the Borg scale. Load will be increased by 2% to 10% when patients can complete 14 or more repetitions in the final set while maintaining the Borg scale between 60% and 80%.~Quadriceps strengthening will be performed at the patient's maximum range guided by symptoms, with pain intensity capped at 5 points on the NPRS. The patient-guided range will be adjusted based on pain intensity, comfort, and patient response, using a shared decision-making approach. The goal is to maintain exercises at the maximum possible range of motion.~For the Leg Extension Machine, Squats, and Bulgarian Squats, the range of motion will be guided by the patient's pain tolerance.
Study: NCT06685458

Intervention type: OTHER
Intervention: Preoperative Clinical and Imaging Feature Evaluation for Predictive Modeling
Description: This study involves preoperative evaluation of clinical and imaging features for constructing a predictive model to differentiate benign and malignant solid pulmonary nodules. Surgical resection is performed to obtain pathological confirmation as the reference standard.

Intervention type: OTHER
Intervention: Preoperative Clinical and Imaging Feature Evaluation for Predictive Modeling
Description: This study involves preoperative evaluation of clinical and imaging features for constructing a predictive model to differentiate benign and malignant solid pulmonary nodules. Surgical resection is performed to obtain pathological confirmation as the reference standard.
Study: NCT06684509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrovastain
Description: atorvaststin 40mg/daily , started before anthracyclin treatment and continued 12 months
Study: NCT06631521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: 600 mg (two 300 mg tablets) taken orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: A loading dose of 360 mg on the first day, followed by 120 mg taken orally once daily.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Performed at least 48 hours and within 2 weeks after the completion of neoadjuvant therapy.
Study: NCT06620744

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sponsor MCG deivce
Description: Unshielded device measuring cardiac magnetic fields.
Study: NCT06617819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CR prosthesis
Description: For patients undergoing simultaneous bilateral knee arthroplasty, different prostheses (CR vs. PS) were randomized to the left or right knee.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PS prosthesis
Description: For patients undergoing simultaneous bilateral knee arthroplasty, different prostheses (CR vs. PS) were randomized to the left or right knee.
Study: NCT06621888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTI164
Description: This intervention uses Full-Spectrum Medicinal Cannabis Plant Extract with a low THC concentration of 0.08% (NTI164), specifically formulated to treat pediatric acute-onset neuropsychiatric syndrome (PANS). The dosing regimen is carefully structured to increase from an initial 5 mg/kg per day up to a maximum of 20 mg/kg, tailored to individual tolerance levels. This gradual titration and the option to extend treatment up to 54 weeks distinguishes it from other interventions that may use different concentrations of THC or shorter treatment durations. The efficacy of NTI164 is rigorously assessed through psychological evaluations and biomarker analyses.
Study: NCT06685523

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subgingival debridement
Description: To be applied 1 times (0. days)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser decontamination
Description: To be applied 3 times

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diyot laser decontamination
Description: To be applied 3 times
Study: NCT05354102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMC128
Description: A live bio-therapeutic product composed of 4 commensal bacterial strains, natural inhabitants of the human intestinal tract.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: A human monoclonal antibody that blocks programmed-death-1 (PD-1). It is a type of immunotherapy and works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer.
Study: NCT06665594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Description: Injection of TXA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline (placebo)
Description: Injection of saline
Study: NCT05667831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alginate silver silver ion dressing
Description: Alginate silver silver ion dressing is a soft, comfortable wound dressing with a high mannuronic acid content. Gels on contact with wound exudate or blood, creating a moist wound environment for optimal wound healing. Silver ions protect the dressing from a range of microorganisms.
Study: NCT04977336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HB/APAP
Description: Capsules for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (matched to VX-548)
Description: Placebo matched to VX-548 for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to VX-548)
Description: Placebo matched to VX-548 for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to HB/APAP)
Description: Placebo matched to HB/APAP for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matched to HB/APAP)
Description: Placebo matched to HB/APAP for oral administration.
Study: NCT06206551

Intervention type: OTHER
Intervention: Spiritual Needs Questionnaire
Description: This questionnaire captures the spiritual needs of patients and is used in its short version (screener).This questionnaire is used as part of standard treatment for all palliative care inpatients.
Study: NCT04398485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION251
Description: ION251 administered by IV infusion
Study: NCT05514873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zilucoplan (RA101495)
Description: Subcutaneous injection
Study: NCT05500248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leave In Situ
Description: Polyps will be left in situ if diminutive (≤5 mm) in size, located in the rectum or sigma and optically diagnosed by the endoscopist using the system to be hyperplastic with high confidence, otherwise resected and sent to pathology.~This behaviour is recommended by guidelines if the endoscopist is expert in optical diagnosis. In this case the endoscopists will be experts and they will also be helped by the CADx system that has shown to exceed the thresholds requested for use in clinical practice in previous trials.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: All identified polyps will be removed and sent to pathology.
Study: NCT05684510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: clear aligners
Description: clear aligners will be applied to the upper and lower arch, then a class II elastics 1\\4 and 6,5 oz will be use from the precision-cut Hook on the maxillary aligner to the button of mandibular first molar

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traditional treatment Fixed appliances with class II elastics.
Description: Agroup of patients in which participants will be undergo to the fixed multibracket treatment (with slot size 0.022 × 0.028 and MBT prescription , after completing leveling and alignment , Elastics will be applied from the hooks of canines brackets to the hooks of lower first molar when the 0.019× 0.025-inch stainless steel archwires placed.
Study: NCT04680065

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2-GDNF gene therapy
Description: Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham (Placebo) Surgery
Description: Bilateral partial burr/twist holes without dural penetration
Study: NCT05930795

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pectopexy
Description: pectopexy: surgery performed by suspending prolapsed uterus or vault to the pectineal ligament

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lateral suspension
Description: lateral suspension: surgery performed by suspending prolapsed uterus or vault to the lateral walls of the abdomen corresponding to the 3 cm anterior superior to the iliac crest
Study: NCT06433622

Intervention type: DIAGNOSTIC_TEST
Intervention: Repeat Thromboelastography with Platelet Mapping
Description: Thromboelastography (TEG) is an assay used by many medical professionals to assess coagulopathy, predict outcomes, and guide treatment. Although TEG does not assess platelet function very well, a TEG with platelet mapping (TEG-PM) assay assesses platelet functioning by measuring the percent of arachidonic acid (AA) and adenosine diphosphate (ADP) that are inhibited in the patient's blood.
Study: NCT06013982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety Reduction Bundle
Description: The Anxiety Reduction Bundle intervention comprises the following resources:~* Stroke Support Group~* Anxiety Reduction Sheet~* Understanding Anxiety Disorder sheet~* Your body's response to anxiety sheet~* Relaxation Tip sheet~* Breathing Tip sheet and video~* A sigh of Relief video
Study: NCT05917223

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk protein ingestion
Description: It's just an acute intervention, so the participant assigned to the Milk protein ingestion group will consume 20 g of milk protein during infusion protocol.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cron protein ingestion
Description: It's just an acute intervention, so the participant assigned to the Corn protein ingestion group will consume 20 g of corn protein isolation during infusion protocol.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Corn+Pea protein ingestion
Description: It's just an acute intervention, so the participant assigned to the Corn+Pea protein ingestion group will consume 20 g of Corn+Pea protein isolation during infusion protocol.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Non-protein, low energy
Description: It's just an acute intervention, so the participant assigned to the Non-protein, low energy group will consume 20 g of carbohydrate during infusion protocol.
Study: NCT06667908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-90301900
Description: JNJ-90301900 will be injected intratumorally and/or intranodally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-90301900
Description: JNJ-90301900 will be injected intratumorally and/or intranodally.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered as intravenous (IV) infusion as cIT.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered as intravenous (IV) infusion as cIT.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Durvalumab will be administered as intravenous (IV) infusion as cIT.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent Chemo/Radiation Therapy (cCRT)
Description: Radiation by intensity modulated radiation therapy (IMRT) will be administered.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent Chemo/Radiation Therapy (cCRT)
Description: Radiation by intensity modulated radiation therapy (IMRT) will be administered.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent Chemo/Radiation Therapy (cCRT)
Description: Radiation by intensity modulated radiation therapy (IMRT) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin
Description: Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin
Description: Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin
Description: Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel
Description: Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel
Description: Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel
Description: Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy.